NewAmsterdam Pharma Company NV
Company Details
Status: Public
Employees: 11-50
Location:
Naarden, The Netherlands
Type:
sample
Technology:
sample
About: NewAmsterdam Pharma - Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. Its mission is to improve patient care in populations where traditional therapies have been unsuccessful or are not tolerated. In April 2020, NewAmsterdam acquired Dezima Pharma from Amgen, including all rights for obicetrapib (TA-8995), a novel, selective, cholesteryl ester transfer protein (CETP) inhibitor. The Company is investigating Obicetrapib as the preferred LDL-c lowering therapy for patients who cannot be treated optimally with current available lipid-lowering therapy or for patients with Atherosclerotic Cardiovascular Disease/Familial Hypercholesterolemia (ASCVD/FH) on maximally tolerated statin therapy.
In January 2021, NewAmsterdam completed its Series A funding round of $196M (€160M) which will support the full Phase 3 development of Obicetrapib.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
NewAmsterdam Pharma Company NV | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.